

May 1, 2008

APA DSM-V Work Group Member

Name, Degree: Juan R. Bustillo, M.D.

Role(s) in Work Group: Member, Psychotic Disorders Work Group

Institutional Affiliation(s): University of New Mexico

City, State: Albuquerque, NM

Biographical Sketch:

Graduated in Medicine from the *Colegio Mayor de Nuestra Senora del Rosario*, Bogota, Colombia in 1985. Completed Residency in Psychiatry at the University of Texas Medical Branch at Galveston, Texas, in 1991. Completed Research Fellowship at the Maryland Psychiatric Research Center, University of Maryland, in 1996. Since then, faculty member at the Department of Psychiatry, University of New Mexico, Albuquerque, NM. Currently, Associate Professor of Psychiatry and Neuroscience. Research interests in the neurochemistry and treatment of schizophrenia.

UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : **CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008**, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

Non-Profit and Advocacy Organizations	Year(s)	Role
American Foundation for Suicide Prevention	2007	Scientific Review Board

The two tables below represent Dr. Bustillo's disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. Bustillo has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

KEY NUMBER: 1. Consultation Fees (include scientific advisory boards) 2. Full- or Part-time Employee 3. Industry-related Grant-Research Support received or pending 4. Honoraria (includes Speakers' Bureau) 5. Stock or other financial options	6. Expert testimony 7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product) 8. Patents received or pending 9. Officer, director/trustee, executive (specify) 10. Other (specify)
--	---

DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007

Commercial or Other Organization	Year(s)	Key #(s)
Pharmastar	2005	10 (competency assessment of rating scales)

UPDATED 4.28.08

DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR

Commercial or Other Organization	Year(s)	Key #(s)
CME LLC	2008	4
Merck	2008	10 (book chapter review)